RecruitingACTRN12615000394549

Renal Replacement Therapy Intensity in Severe Acute Kidney Injury: An Individual Patient Data Meta-analysis of Randomized Trials

Renal Replacement Therapy Intensity in Severe Acute Kidney Injury and its Effect on All-cause Mortality and Recovery to Dialysis Independence: An Individual Patient Data Meta-analysis of Randomized Trials


Sponsor

The George Institute for Global Health

Enrollment

3,600 participants

Start Date

Apr 9, 2015

Study Type

Observational

Conditions

Summary

Renal replacement (RRT) dose intensity may affect patient and kidney outcomes in severe acute kidney injury (AKI) but randomized controlled trial (RCTs) have been contradictory for mortality and inadequately powered for renal outcomes. The Investigation, Management, Prognosis, Recovery, Observation, Value and Evaluation of Acute Kidney Injury (IMPROVE-AKI) collaboration brings together investigators from current randomised clinical trials of RRT dose intensity in AKI to perform IPDMA of the effects of RRT dose intensity.


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This is a research analysis study (not a clinical trial requiring patient participation) that combines data from multiple existing clinical trials to better understand whether giving more or less dialysis to critically ill patients with severe acute kidney injury (AKI) improves their chances of survival and kidney recovery. Different trials have reached different conclusions, so this study pools all the data together to get a clearer answer. You may be eligible if: - You have participated in a randomised controlled trial comparing different doses of renal replacement therapy (dialysis) for acute kidney injury You may NOT be eligible if: - You have chronic kidney disease (pre-existing long-term kidney failure) Talk to your doctor about whether this trial might be right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Higher intensity haemodialysis, a prescribed dose of 35 to 48 ml/kg/h or defined as published in the original publications

Higher intensity haemodialysis, a prescribed dose of 35 to 48 ml/kg/h or defined as published in the original publications


Locations(5)

United States of America

Netherlands

Germany

Italy

Switzerland

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12615000394549